Core Insights - Compass Therapeutics, Inc. is approaching a significant milestone with the upcoming top-line data readout for its Phase 2/3 study of tovecimig in patients with advanced biliary tract cancer (BTC) expected at the end of Q1 2025 [2][6] - The company has introduced a new drug candidate, CTX-10726, a PD-1 x VEGF-A bispecific antibody, with an IND submission anticipated by the end of 2025 and initial clinical data expected in 2026 [2][6][12] - Compass is progressing with two new Phase 2 biomarker studies, one for tovecimig and another for CTX-471, both expected to start in mid-2025 [2][6] Development Pipeline Updates - Tovecimig (CTX-009) is a DLL4 x VEGF-A bispecific antibody with a top-line data readout scheduled for the end of Q1 2025 in patients with BTC [3][6] - CTX-471 is a CD137 agonist antibody, with a Phase 2 trial initiation expected in mid-2025 targeting tumors expressing NCAM/CD56 [4][6] - CTX-8371 is a PD-1 x PD-L1 bispecific antibody, with the third dosing cohort of its Phase 1 study fully enrolled and preliminary data expected in the second half of 2025 [5][6][12] Financial Position - As of December 31, 2024, Compass Therapeutics reported an estimated $127 million in cash and marketable securities, which is projected to sustain operations into Q1 2027 [9][6]
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate